Relief Therapeutics announces promising PKU treatment results for RLF-OD032, similar to KUVAN® powder with water-free administration.

Relief Therapeutics Holding SA announced promising results from its proof-of-concept study for RLF-OD032, a concentrated liquid formulation of sapropterin dihydrochloride aimed at treating phenylketonuria (PKU). The study showed RLF-OD032's effectiveness similar to KUVAN® powder, with the added benefit of being administered without water, enhancing patient convenience. The company plans to proceed with a pivotal bioequivalence trial as part of its NDA submission in the U.S.

October 04, 2024
7 Articles